NAMPT and PARylation Are Involved in the Pathogenesis of Atopic Dermatitis
International Journal of Molecular Sciences · 28.04.2023 · 24 (9) · 7992
DOI: 10.3390/ijms24097992 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.04.2023. Verfasst von Ana B Arroyo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inmunidad, Inflamación y Cáncer, Departamento de Biología Celular e Histología, Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MCIN/AEI/10.13039/501100011033, MCINN/ISCIII.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic inflammatory skin disease of very high prevalence, especially in childhood, with no specific treatment or cure. As its pathogenesis is complex, multifactorial and not fully understood, further research is needed to increase knowledge and develop new targeted therapies. We have recently demonstrated the critical role of NAD+ and poly (ADP-ribose) (PAR) metabolism in oxidative stress and skin inflammation. Specifically, we found that hyperactivation of PARP1 in response to DNA damage induced by reactive oxygen species, and fueled by NAMPT-derived NAD+, mediated inflammation through parthanatos cell death in zebrafish and human organotypic 3D skin models of psoriasis. Furthermore, the aberrant induction of NAMPT and PARP activity was observed in the lesional skin of psoriasis patients, supporting the role of these signaling pathways in psoriasis and pointing to NAMPT and PARP1 as potential novel therapeutic targets in treating skin inflammatory disorders. In the present work, we report, for the first time, altered NAD+ and PAR metabolism in the skin of AD patients and a strong correlation between NAMPT and PARP1 expression and the lesional status of AD. Furthermore, using a human 3D organotypic skin model of AD, we demonstrate that the pharmacological inhibition of NAMPT and PARP reduces pathology-associated biomarkers. These results help to understand the complexity of AD and reveal new potential treatments for AD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inmunidad, Inflamación y Cáncer, Departamento de Biología Celular e Histología, Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain.
- Instituto Murciano de Investigación Biosanitaria (IMIB)-Pascual Parrilla, 30120 Murcia, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.
ORCID-Profile: Ana B Arroyo, María L Cayuela, Victoriano Mulero
Förderung
- MCIN/AEI/10.13039/501100011033
- MCINN/ISCIII
Zitieren
APA
Arroyo, A. B., Bernal-Carrión, M., Cantón-Sandoval, J., Cabas, I., Corbalán-Vélez, R., Martínez-Menchón, T., Ferri, B., Cayuela, M. L., García-Moreno, D., & Mulero, V. (2023). NAMPT and PARylation Are Involved in the Pathogenesis of Atopic Dermatitis. International Journal of Molecular Sciences, 24(9), 7992. https://doi.org/10.3390/ijms24097992
Vancouver
Arroyo AB, Bernal-Carrión M, Cantón-Sandoval J, Cabas I, Corbalán-Vélez R, Martínez-Menchón T, et al. NAMPT and PARylation Are Involved in the Pathogenesis of Atopic Dermatitis. International Journal of Molecular Sciences. 2023;24(9):7992. doi:10.3390/ijms24097992
BibTeX
@article{Arroyo2023,
author = {Arroyo, Ana B and Bernal-Carrión, Martín and Cantón-Sandoval, Joaquín and Cabas, Isabel and Corbalán-Vélez, Raúl and Martínez-Menchón, Teresa and Ferri, Belén and Cayuela, María L and García-Moreno, Diana and Mulero, Victoriano},
title = {NAMPT and PARylation Are Involved in the Pathogenesis of Atopic Dermatitis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {9},
pages = {7992},
doi = {10.3390/ijms24097992}
}
EUVIMED